Orkambi

(asked on 5th December 2016) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment has been made of the effectiveness of Orkambi in improving life expectancy for people with cystic fibrosis.


This question was answered on 13th December 2016

The National Institute for Health and Care Excellence (NICE) is the independent body that develops guidance for the National Health Service on whether new drugs and treatments represent a clinically and cost effective use of resources.

NICE published final guidance on the use of Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis homozygous for the F508del mutation in July 2016 that does not recommend this treatment.

Where NICE has not been able to recommend a treatment, funding decisions should be made by the relevant NHS commissioner, based on an assessment of the available evidence.

Reticulating Splines